Expertise in
27
conditions

Dr. Stephen J. Schuster

Hematology
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
27
conditions
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 

Overview

Stephen Schuster is a Hematologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Schuster is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Schuster is board certified in Hematology, 1986, Internal Medicine, 1984, and Medical Oncology, 1989. He is actively involved in clinical research, co-authoring 235 peer reviewed articles and participating in 12 clinical trials. Dr. Schuster is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in PA

Board Certifications

Hematology, 1986
Internal Medicine, 1984
Medical Oncology, 1989

Fellowships

Thomas Jefferson University Hospital
Pennsylvania Hospital

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Lancaster General Hospital
Penn Presbyterian Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Schuster has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Burkitt Lymphoma
Langerhans Cell Histiocytosis
Hodgkin Lymphoma
Waldenstrom Macroglobulinemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Drug
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 2
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2025
Intervention Type: Other, Device
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Terminated
Publish Date: January 31, 2023
Intervention Type: Biological, Drug
Study Drugs: Tisagenlecleucel, Ibrutinib
Study Phase: Phase 1
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Enrollment Status: Completed
Publish Date: August 15, 2022
Intervention Type: Drug, Biological
Study Drugs: Tisagenlecleucel, Pembrolizumab
Study Phase: Phase 1
View 9 Less Clinical Trials

235 Total Publications

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
Journal: Nature medicine
Published: August 26, 2026
Similar Doctors
Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stefan Barta is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Barta is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Barta is board certified in Medical Oncology, 2010 and Hematology, 2010. Dr. Barta is currently accepting new patients.

Expertise in
28
conditions
Dr. Adam Cuker
Hematology
Expertise in
28
conditions
Dr. Adam Cuker
Hematology
Referral may be required
Before you request

Penn Blood Disorders Center

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-6555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Cuker is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cuker is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Splenectomy, and Knee Replacement. Dr. Cuker is board certified in Hematology, 2009. Dr. Cuker is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Landsburg is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Landsburg is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Landsburg is board certified in Medical Oncology, 2014. Dr. Landsburg is currently accepting new patients.

Frequently Asked Questions about Dr. Stephen J. Schuster

How do I make an appointment with Dr. Stephen J. Schuster?

You can book an appointment with Dr. Stephen J. Schuster by calling their office at 215-615-5858. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen J. Schuster a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen J. Schuster is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen J. Schuster specialize in?

While Dr. Stephen J. Schuster is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Follicular Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Stephen J. Schuster participate in research or clinical trials?

Yes. Dr. Stephen J. Schuster has published 235 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Stephen J. Schuster's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen J. Schuster accept my insurance?

Dr. Stephen J. Schuster accepts most major insurance plans, including Aetna and CareFirst. We recommend calling the office directly at 215-615-5858 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schuster's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 13 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile